Epstein Secrets

4918 treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefit

ing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

y difficult to treat with high levels of LDL cholesterol,” says Steven HOUSE_OVERSIGHT_025888 --- PAGE BREAK --- Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

w us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for